Drug Trial Radar · NCT00659971
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
Last checked: Nov 19, 2026Latest source record: Jun 26, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
223
Actual
Start
Jan 2008
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Pacgen Biopharmaceuticals CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Quintiles, Inc.
- First posted
- Apr 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment of oral candidiasis in HIV seropositive patients.
Conditions
- Oral Candidiasis
Interventions
PAC113Drug
PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eliminating or reducing clinical signs and symptoms of oral Candida infections.Time frame: Day 19
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rosedale Infectious Disease
Huntersville, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.